Literature DB >> 23412775

The influence of regional health system characteristics on the surgical management and receipt of post operative radiation therapy for glioblastoma multiforme.

Sanjay Aneja1, Dhruv Khullar, James B Yu.   

Abstract

Despite a known optimal treatment protocol for the management of glioblastoma multiforme (GBM), many patients fail to receive complete surgical resection or post-operative radiation therapy (PORT). The underlying reasons behind this disparity are unclear. Our study investigates the influence of regional health system resources on the surgical management and PORT receipt in patients with GBM. Surgical intervention, PORT receipt and patient data for patients diagnosed with GBM were obtained from the years 2004 to 2008 from the NCI Surveillance, Epidemiology, and End Results database and combined with the health system data from the Area Resource File. Four logistic models were constructed to test the effect of health system characteristics on surgical treatment choice and PORT receipt among health service areas (HSAs). We found that younger, married patients in HSAs with higher median incomes were significantly more likely to receive both gross total resection (p < 0.001, p < 0.001, p = 0.002) and PORT (p < 0.001, p < 0.001, p = 0.008). The density of radiation oncology equipped hospitals was also a significant predictor of PORT receipt (p = 0.002). Our findings suggest regional variations in of neuro-oncology services and income may have impact on GBM management. Policies aimed at narrowing disparities in treatment may need to focus on addressing regional variations in oncology resources.

Entities:  

Mesh:

Year:  2013        PMID: 23412775      PMCID: PMC3641833          DOI: 10.1007/s11060-013-1068-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  33 in total

1.  Racial disparities in Hodgkin's lymphoma: a comprehensive population-based analysis.

Authors:  A M Evens; M Antillón; B Aschebrook-Kilfoy; B C-H Chiu
Journal:  Ann Oncol       Date:  2012-01-11       Impact factor: 32.976

2.  The effects of specialist supply on populations' health: assessing the evidence.

Authors:  Barbara Starfield; Leiyu Shi; Atul Grover; James Macinko
Journal:  Health Aff (Millwood)       Date:  2005 Jan-Jun       Impact factor: 6.301

3.  Marital status, treatment, and survival in patients with glioblastoma multiforme: a population based study.

Authors:  Susan M Chang; Fred G Barker
Journal:  Cancer       Date:  2005-11-01       Impact factor: 6.860

4.  Improving prognosis of glioblastoma in the 21st century: who has benefited most?

Authors:  Yaacov Richard Lawrence; Mark V Mishra; Maria Werner-Wasik; David W Andrews; Timothy N Showalter; Jon Glass; Xinglei Shen; Zvi Symon; Adam P Dicker
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

5.  Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection.

Authors:  J Shinoda; N Sakai; S Murase; H Yano; T Matsuhisa; T Funakoshi
Journal:  J Neurooncol       Date:  2001-04       Impact factor: 4.130

6.  Improved survival after gross total resection of malignant gliomas in pediatric patients from the HIT-GBM studies.

Authors:  Christof M Kramm; Sabine Wagner; Stefan Van Gool; Hansjörg Schmid; Ronald Sträter; Astrid Gnekow; Stefan Rutkowski; Johannes E A Wolff
Journal:  Anticancer Res       Date:  2006 Sep-Oct       Impact factor: 2.480

7.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

8.  Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group.

Authors:  K Kristiansen; S Hagen; T Kollevold; A Torvik; I Holme; R Nesbakken; R Hatlevoll; M Lindgren; A Brun; S Lindgren; G Notter; A P Andersen; K Elgen
Journal:  Cancer       Date:  1981-02-15       Impact factor: 6.860

9.  Association of socioeconomic status with functional capacity, heart rate recovery, and all-cause mortality.

Authors:  Mehdi H Shishehbor; David Litaker; Claire E Pothier; Michael S Lauer
Journal:  JAMA       Date:  2006-02-15       Impact factor: 56.272

10.  Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project.

Authors:  Edward R Laws; Ian F Parney; Wei Huang; Fred Anderson; Angel M Morris; Anthony Asher; Kevin O Lillehei; Mark Bernstein; Henry Brem; Andrew Sloan; Mitchel S Berger; Susan Chang
Journal:  J Neurosurg       Date:  2003-09       Impact factor: 5.115

View more
  10 in total

1.  Quality improvement in neurology: Neuro-Oncology Quality Measurement Set.

Authors:  Justin T Jordan; Amy E Sanders; Terri Armstrong; Tony Asher; Amy Bennett; Erin Dunbar; Nimish Mohile; P Leia Nghiemphu; Timothy R Smith; Douglas E Ney
Journal:  Neuro Oncol       Date:  2018-03-27       Impact factor: 12.300

2.  Characteristics and survival outcomes associated with the lack of radiation in the treatment of glioblastoma.

Authors:  Bin Huang; Therese A Dolecek; Quan Chen; Catherine R Garcia; Thomas Pittman; John L Villano
Journal:  Med Oncol       Date:  2018-04-17       Impact factor: 3.064

3.  Improved survival for elderly married glioblastoma patients : Better treatment delivery, less toxicity, and fewer disease complications.

Authors:  Florian Putz; Tobias Putz; Nicole Goerig; Stefan Knippen; Thomas Gryc; Ilker Eyüpoglu; Karl Rössler; Sabine Semrau; Sebastian Lettmaier; Rainer Fietkau
Journal:  Strahlenther Onkol       Date:  2016-09-14       Impact factor: 3.621

4.  Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma.

Authors:  Ryan Rhome; Rebecca Fisher; Adília Hormigo; Rahul R Parikh
Journal:  J Neurooncol       Date:  2016-03-12       Impact factor: 4.130

Review 5.  Epidemiologic and molecular prognostic review of glioblastoma.

Authors:  Jigisha P Thakkar; Therese A Dolecek; Craig Horbinski; Quinn T Ostrom; Donita D Lightner; Jill S Barnholtz-Sloan; John L Villano
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-07-22       Impact factor: 4.254

6.  Management of glioblastoma at safety-net hospitals.

Authors:  Michael G Brandel; Robert C Rennert; Christian Lopez Ramos; David R Santiago-Dieppa; Jeffrey A Steinberg; Reith R Sarkar; Arvin R Wali; J Scott Pannell; James D Murphy; Alexander A Khalessi
Journal:  J Neurooncol       Date:  2018-04-24       Impact factor: 4.130

7.  Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA.

Authors:  Allicia C Girvan; Gebra C Carter; Li Li; Anna Kaltenboeck; Jasmina Ivanova; Maria Koh; Jessi Stevens; Eleanor Hayes-Larson; Michael M Lahn
Journal:  Drugs Context       Date:  2015-03-10

8.  Surgery for CNS Tumors in the Brazilian National Health Care System.

Authors:  Luciola Pontes; Maryam Nemati Shafaee; Benjamin Haaland; Gilberto Lopes
Journal:  J Glob Oncol       Date:  2016-07-06

Review 9.  Combining Nonclinical Determinants of Health and Clinical Data for Research and Evaluation: Rapid Review.

Authors:  Elizabeth Golembiewski; Katie S Allen; Amber M Blackmon; Rachel J Hinrichs; Joshua R Vest
Journal:  JMIR Public Health Surveill       Date:  2019-10-07

10.  Identifying Disparities in Care in Treating Glioblastoma: A Retrospective Cohort Study of Patients Treated at a Safety-net Versus Private Hospital Setting.

Authors:  Theodore Wang; Anthony Pham; Stella Yoo; Frank J Attenello; Richard Jennelle; Naveed Wagle; Eric L Chang; Gabriel Zada
Journal:  World Neurosurg       Date:  2020-01-27       Impact factor: 2.104

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.